<DOC>
	<DOCNO>NCT01998646</DOCNO>
	<brief_summary>The purpose study explore safety , tolerability pharmacokinetics ( PK ) single ascend oral dos ASP4058 non-elderly , healthy male female subject . This study also explore effect food PK ASP4058.The food-effect crossover group open-label treatment placebo control .</brief_summary>
	<brief_title>A Dose Escalation Study Assess Safety , Tolerability , Pharmacokinetics ASP4058 Following Single Oral Doses</brief_title>
	<detailed_description>Subjects remain clinic 9 day . Subjects return clinic follow-up day 12 30 collect additional safety information .</detailed_description>
	<criteria>The female subject must least two year postmenopausal ( define least 2 year Screening without menses confirmatory follicle stimulate hormone ( FSH ) level ≥ 40 U/L Screening ) surgically sterile ( documentation provide healthcare professional ) pregnant lactating . The male subject agree sexual abstinence , surgically sterile ( documentation provide healthcare professional ) , use medically acceptable method ( e.g. , spermicide diaphragm , spermicide condom ) prevent pregnancy agree continue use method end study 29 day postdose , whichever longer . The subject must normal ( ≥ 80 % normal range ) respiratory function define spirometry , measure forced expiratory volume ( FEV1 ) force vital capacity ( FVC ) relative establish normal range adjust age sex . The subject Screening Day 2 , must color vision testing , acuity testing ( correct ) , fundoscopic exam within normal limit opinion examining/reviewing ophthalmologist . The subject 's total lymphocyte count Screening must &gt; 1.0 x 103/uL . The subject highly likely comply protocoldefined procedure complete study . The subject positive herpes simplex virus ( HSV ) 1 and/or HSV2 antibody Screening . The subject current smoker history routinely smoke ( &gt; 10 cigarettes/day ) within last seven years.. The subject history clinically significant bradyarrhythmia sinus bradycardia . The subject condition possibly affect drug absorption ( e.g. , gastrectomy ) . The subject history consume 14 unit alcoholic beverage per week average within 6 month prior Screening history alcoholism drug/chemical/substance abuse within past 2 year prior Screening subject test positive Screening clinic admission alcohol drug abuse ( amphetamine , barbiturate , benzodiazepine , cannabinoids , cocaine , opiates ) . The subject has/had febrile illness symptomatic , viral , bacterial ( include upper respiratory infection ) , fungal ( noncutaneous ) infection within 2 week prior clinic check . The subject supine mean systolic blood pressure &lt; 90 &gt; 140 mmHg mean diastolic blood pressure &lt; 50 &gt; 90 mmHg , mean heart rate &gt; 100 &lt; 55 beat per minute ( bpm ) , either Screening clinic check ( measurement take triplicate subject rest supine position minimum 5 minute ) . The subject 12lead electrocardiogram ( ECG ) demonstrate QTcF &gt; 450 msec ( female ) &gt; 430 msec ( male ) Screening . If QTcF exceed limit , ECG repeat two time average three QTcF value use determine subject 's eligibility . The subject diagnose glaucoma currently treat glaucoma . The subject know positive human immunodeficiency virus ( HIV ) antibody . The subject currently use Latisse® ( eyelash lengthen medication ) use within last 30 day . The subject positive test hepatitis C antibody ( HCV ) , positive hepatitis B antigen ( HBsAg ) Screening . The subject use prescription nonprescription drug within 2 week 5 half life ( whichever longer ) complementary alternative medicine ( CAM ) within 28 day prior study drug administration ( exclude hormone replacement therapy [ HRT ] acetaminophen ) . The subject participate clinical trial receive experimental agent participate clinical trial approve therapy investigational use within 30 day ten halflives , whichever longer , prior study drug administration . The subject vaccinate within last 60 day . The subject significant blood loss , donate one unit ( 450 mL ) blood , receive transfusion blood blood product within 60 day donate plasma within 7 day prior clinic admission Day 2 . The subject know positive tuberculosis test positive Screening .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2013</verification_date>
	<keyword>ASP4058</keyword>
	<keyword>healthy subject</keyword>
</DOC>